Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.
about
Assessment of Alzheimer's disease case-control associations using family-based methodsEndothelin-converting enzymes and related metalloproteases in Alzheimer's diseaseThe influence of chronic cerebral hypoperfusion on cognitive function and amyloid β metabolism in APP overexpressing miceAngiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive declineAlterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice.Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.ACE variants and association with brain Aβ levels in Alzheimer's diseaseIdentification and characterization of Aβ peptide interactors in Alzheimer's disease by structural approaches.Renin angiotensin system and gender differences in dopaminergic degeneration.Granulocyte-colony stimulating factor attenuates oligomeric amyloid β neurotoxicity by activation of neprilysin.Telmisartan Modulates Glial Activation: In Vitro and In Vivo StudiesThe Role of the Renin-Angiotensin System in Amyloid Metabolism of Alzheimer's DiseaseSecreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1.Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer's diseaseCurrent and future therapy in Alzheimer's disease.The AbetaCs of Abeta-cleaving proteases.Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele.Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.Current perspectives on pharmacotherapy of Alzheimer's disease.Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?The beneficial role of vitamin D in Alzheimer's disease.New and emerging treatments for Alzheimer's disease.New and emerging treatments for Alzheimer's disease.Proteolytic degradation of amyloid β-protein.The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms.Aβ degradation or cerebral perfusion? Divergent effects of multifunctional enzymes.Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.Progress in the development of new drugs in Alzheimer's disease.Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro.Zinc metalloproteinases and amyloid Beta-Peptide metabolism: the positive side of proteolysis in Alzheimer's disease.Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.Angiotensin II-inhibition: effect on Alzheimer's pathology in the aged triple transgenic mouse.Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer's disease.Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.Physiological and pathophysiological functions of different angiotensins in the brain.Exceptional in vivo catabolism of neurodegeneration-related aggregates.Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?
P2860
Q24622654-68756858-F4AD-459D-A76E-E67836DC6A84Q26862901-6988420C-1886-41A0-A582-31F6BEC441CBQ30477118-95DE8607-E7C9-4369-B8A2-C5C52E9005E2Q30572684-27066DFC-BAE2-4098-94D9-7ABA1C788D8CQ30678146-C3B663A6-22A3-4864-A389-8B8355906D10Q30833707-569C26FD-870B-4326-8676-E9358A3FF6C0Q33652202-4CA196EA-D4F9-44D3-9008-A8C5987EB6A6Q34110227-79F80D79-E044-4FAF-9F1A-C049F9AAFD56Q34310258-83530946-7CA7-4555-BB88-374871D789B0Q34312807-921379DB-4C65-4E3D-8420-32CB19C81F4DQ35203828-7FAC7279-E286-4BCD-BAA4-1779FC6B4BA6Q35213148-70F4AEE4-8457-4C71-B551-D2DB34C30FE9Q36019970-C2CF7B5E-3B72-4A14-AA28-52F06327E654Q36721915-067A86ED-5DB2-41BC-AA0F-C63A66975158Q36740945-0CDB2C73-B1F0-452D-823A-BFFC8418C3AFQ36764094-55832EC1-2610-4B70-A467-AC38412F628BQ37139242-C06D14C5-70A1-492C-BDC6-7BA5144BEF93Q37165703-F571003F-4895-4168-83E6-E92E6C209588Q37250796-2EB06221-923A-44E9-8E8A-5D4DE5D12A79Q37415248-2AB4635B-867A-453C-B0AF-E10ABD3F8AADQ37600876-2E94B004-8182-4068-AD40-DA6B09B5AD9FQ37827489-61F0B41D-C587-4891-A4E7-2530C1D299ABQ37961852-B668DA01-8281-46EE-90B7-D25DDEA9E08CQ37971804-C4B821C7-7C2E-41B5-BC87-A9FEF9186E4AQ37996072-BE1A8026-8313-43B6-B9D6-901B5AC81ED7Q38006979-6229B425-0E5A-4316-AC56-203DA5A63E8AQ38016899-DC425B65-5CA8-4DC0-A9E1-E8CD3B3F90C2Q38108100-BFE567BA-E5C1-45A0-89F4-6AD0F87E9D9AQ38259551-2F8393F7-5C7F-4114-80D9-796F9B3047A0Q38781022-6CE569AA-353B-46F8-B898-6CF1D0CDEA56Q39789745-8CCBB641-C1B3-4D96-8C50-347D15EE95EAQ40075301-EC627F92-554D-416B-B185-7C15529EFBB3Q41680485-DF15C085-B116-443B-A32D-835B616773EAQ41840991-F79244EC-FFF5-42A3-A568-0C6399584D25Q42069095-A7DE3D2A-93B4-41B8-A77A-B6E19B074843Q42069122-A2D779B4-FC7A-4E9F-AE7D-8C4A53E0C19CQ42561537-E4130054-144A-4C84-9635-F4F23AB2556AQ46322831-B3154A4D-B771-4ABA-A889-77AFB0EE533AQ48043354-D3A4AECB-37DB-41B1-B094-606B9915671CQ48352528-363FE06B-1578-47E5-A57D-EAEB6911358A
P2860
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Effects of prolonged angiotens ...... e models of Alzheimer disease.
@en
type
label
Effects of prolonged angiotens ...... e models of Alzheimer disease.
@en
prefLabel
Effects of prolonged angiotens ...... e models of Alzheimer disease.
@en
P2093
P2860
P1476
Effects of prolonged angiotens ...... e models of Alzheimer disease.
@en
P2093
Dennis J Selkoe
Matthew L Hemming
Wesley Farris
P2860
P304
P356
10.1016/J.NBD.2007.01.004
P577
2007-01-25T00:00:00Z